Ocular Therapeutix (OCUL) interim CFO discloses RSUs and stock options
Rhea-AI Filing Summary
Ocular Therapeutix, Inc. filed an initial ownership report for interim CFO Jason Shand Robins, detailing his equity holdings in the company as of January 20, 2026. He directly holds 52,656 shares of common stock, which include 20,917 unvested RSUs from a January 13, 2025 grant and 22,425 unvested RSUs from a January 2, 2026 grant. Each RSU represents one share of common stock and is scheduled to vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in equal yearly installments.
Robins also holds two stock option awards: one covering 110,600 shares of common stock at an exercise price of $8.12 per share, expiring on January 12, 2035, and another covering 68,195 shares at $11.82 per share, expiring on January 1, 2036. The first option, granted on January 13, 2025, vests over four years with 25% vesting on January 13, 2026 and the balance vesting monthly over the following three years. The second option, granted on January 2, 2026, vests over four years with 1/48 of the underlying shares vesting monthly starting one month after the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Includes 20,917 restricted stock units ("RSUs") remaining unvested pursuant to an award of 31,375 RSUs granted under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on January 13, 2025, and 22,425 RSUs remaining unvested pursuant to an award of 22,425 RSUs granted under the Corporation's 2021 Stock Incentive Plan, as amended, on January 2, 2026. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, with 1/3 of the shares underlying the RSUs vesting on the one-year anniversary of the respective date of grant and an additional 1/3 of the shares underlying the RSUs vesting at the end of each successive one-year period thereafter. This option was granted on January 13, 2025 and vests over four years, with 25% of the original number of shares vesting on January 13, 2026 and the remainder vesting in equal monthly installments over the three years after such date. This option was granted on January 2, 2026 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on the one-month anniversary of the grant date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
Who is the reporting insider in Ocular Therapeutix (OCUL)'s latest Form 3?
The reporting insider is Jason Shand Robins, who serves as Interim CFO of Ocular Therapeutix, Inc. and is filing as a single reporting person.
What RSU awards are included in the interim CFO's Ocular Therapeutix (OCUL) holdings?
His holdings include 20,917 unvested RSUs from a grant of 31,375 RSUs on January 13, 2025 under the 2019 Inducement Stock Incentive Plan and 22,425 unvested RSUs from a grant on January 2, 2026 under the 2021 Stock Incentive Plan.
How do the RSUs for Ocular Therapeutix (OCUL) interim CFO vest?
Subject to continued service, each RSU grant vests over three years: 1/3 of the shares vests on the one-year anniversary of the grant date and an additional 1/3 vests at the end of each of the next two years.
What stock options does the Ocular Therapeutix (OCUL) interim CFO hold and at what prices?
He holds two stock option awards: one for 110,600 shares at an exercise price of $8.12 per share expiring on January 12, 2035, and another for 68,195 shares at $11.82 per share expiring on January 1, 2036, both held directly.
What are the vesting schedules of the Ocular Therapeutix (OCUL) interim CFO's stock options?
The option granted on January 13, 2025 vests over four years, with 25% vesting on January 13, 2026 and the remainder vesting in equal monthly installments over the next three years. The option granted on January 2, 2026 vests over four years with 1/48 of the shares vesting monthly starting one month after the grant date.